The following abstracts showcase the top cutting-edge research presented at the European Society for Medical Oncology (ESMO) ...

This Industry Satellite Symposium was presented at the European Society for Medical Oncology (ESMO) Congress 2024, held in ...

Seeing the disappointing post ESMO selloff (across a number of companies ... The impact of AbbVie's Elahere is misrepresented in my eyes, as NCCN guidelines recommend its use with Avastin in ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to ...

Novartis ribociclib recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Guidelines: Basel Saturday, October 26, 2024, 14:00 Hrs [IST] This month, the NCCN ...

Precision genomics company, Nonacus Ltd, has launched GALEASTM uPCR ESR1, an ultrasensitive qPCR (uPCR) assay developed to detect eleven mutations in the ESR1 gene which are known to be associated ...

In September, Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz ®) and initial data from the Phase 1 ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

In an interview with Targeted Oncology, Peter Schmid, MD, PhD, discussed the results from the phase 3 KEYNOTE-522 trial.

Studies have called into question whether patients with HER2-low breast cancer are being identified and classified accurately.

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...